2. Search Result
Search Result
Results for "

Oligomerization

" in MedChemExpress (MCE) Product Catalog:

50

Inhibitors & Agonists

2

Peptides

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145580
    Minzasolmin

    UCB0599; (R)-NPT200-11

    		 α-synuclein Neurological Disease
    Minzasolmin is an alpha-synuclein oligomerization inhibitor .
    Minzasolmin
  • HY-129122
    VBIT-4
    Maximum Cited Publications
    8 Publications Verification

    		 VDAC Cardiovascular Disease Neurological Disease
    VBIT-4 is an inhibitor of voltage-dependent anion channel 1 (VDAC1) oligomerization with a binding affinity (Kd) of 17 μM. VBIT-4, as an apoptosis inhibitor, can be used for therapeutic purposes in apoptosis-associated disorders, such as neurodegenerative and cardiovascular diseases .
    VBIT-4
  • HY-161296
    TH6342

    		Bacterial HIV Infection
    TH6342 is a SAMHD1 modulator that binds to pretetrameric SAMHD1 and prevents its oligomerization and allosteric activation. SAMHD1 is a dNTP triphosphohydrolase and an HIV-1 restriction factor. SAMHD1 can limit the replication of retroviruses and DNA viruses and has antiviral effects. The inhibitory mechanism of TH6342 does not occupy the SAMHD1 nucleotide-binding pocket, gently binds the target, and functions as a chemical probe .
    TH6342
  • HY-149237
    hAChE-IN-2

    		Cholinesterase (ChE) Tau Protein Neurological Disease
    hAChE-IN-2 is a potent hAChE inhibitor, with an IC50 of 0.71 μM. hAChE-IN-2 can also inhibits tau-oligomerization, with an EC50 of 2.21 μM. hAChE-IN-2 exhibits neuroprotective activity .
    hAChE-IN-2
  • HY-156179
    DDC 2′,3′-O-disulfate

    		Amyloid-β Neurological Disease
    DDC 2′,3′-O-disulfate (compound 4) prevents the fibrillization and oligomerization of Aβ42. DDC 2′,3′-O-disulfate has the potential for Alzheimer's disease (AD) research .
    DDC 2′,3′-O-disulfate
  • HY-156180
    DDC 3′-O-β-D glucuronide

    		Drug Metabolite Neurological Disease
    DDC 3′-O-β-D glucuronide (compound 5) is a drug metabolite that can prevent the fibrillization and oligomerization of Aβ42. DDC 3′-O-β-D glucuronide has potential for the research of Alzheimer's disease .
    DDC 3′-O-β-D glucuronide
  • HY-101112
    Okicenone

    		HuR Inflammation/Immunology
    Okicenone is a Hu protein R (HuR) inhibitor. Okicenone inhibits HuR oligomerization, interferes with HuR RNA binding, HuR trafficking, cytokine expression and T-cell activation .
    Okicenone
  • HY-17406S
    Tolcapone-d7

    Ro 40-7592 d7

    		 Isotope-Labeled Compounds COMT Amyloid-β Neurological Disease
    Tolcapone-d7 is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells[1][2].
    Tolcapone-d7
  • HY-156374
    D359-0396

    		NOD-like Receptor (NLR) Pyroptosis Inflammation/Immunology
    D359-0396 is an orally active NLRP3 inflammasome inhibitor. D359-0396 inhibits pyroptosis and IL-1β release in macrophages. D359-0396 also inhibits the oligomerization of NLRP3, ASC and the cleavage of GSDMD. D359-0396 alleviates EAE, and also improves survival after septic shock in mice .
    D359-0396
  • HY-149604
    NLRP3-IN-21

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NLRP3-IN-21 (compound L38) is a NLRP3 inflammasome inhibitor with inflammatory properties. NLRP3-IN-21 inhibits NLRP3 inflammasome activation and pyroptosis by suppressing gasdermin D cleavage, ASC oligomerization, and NLRP3 inflammasome assembly .
    NLRP3-IN-21
  • HY-120079
    MSN-125
    2 Publications Verification

    		 Bcl-2 Family Apoptosis Cancer
    MSN-125 is a potent Bax and Bak oligomerization inhibitor. MSN-125 prevents mitochondrial outer membrane permeabilization (MOMP) with an IC50 of 4 μM. MSN-125 potently inhibits Bax/Bak-mediated apoptosis in HCT-116, BMK Cells, and primary cortical neurons, protects primary neurons against glutamate excitotoxicity .
    MSN-125
  • HY-161242
    CBI1

    		Bcl-2 Family Cancer
    CBI1 is a covalent BAX inhibitor. CBI1 selectively derivatizes BAX at C126 and inhibits BAX activation by triggering ligands or point mutagenesis. CBI1 blocks t-2-hex lipidation and oligomerization of BAX. CBI1 inhibits BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex .
    CBI1
  • HY-136735
    IRE1α kinase-IN-1

    		IRE1 Neurological Disease Cancer
    IRE1α kinase-IN-1 is a highly selective IRE1α (ERN1) inhibitor, with an IC50 of 77 nM. IRE1α kinase-IN-1 displays 100-fold selectivity for IRE1α over the IRE1β isoform. IRE1α kinase-IN-1 inhibits ER stress-induced IRE1α oligomerization and autophosphorylation, and also inhibits IRE1α RNase activity (IC50=80 nM) .
    IRE1α kinase-IN-1
  • HY-U00460
    3,6-DMAD hydrochloride

    		IRE1 Cancer
    3,6-DMAD hydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD hydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD hydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD hydrochloride can be used for research of cancer .
    3,6-DMAD hydrochloride
  • HY-U00460B
    3,6-DMAD dihydrochloride

    		IRE1 Cancer
    3,6-DMAD dihydrochloride, an acridine derivative, is a potent IRE1α-XBP1s pathway inhibitor. 3,6-DMAD dihydrochloride promotes IL-6 secretion via the IRE1α-XBP1s pathway. 3,6-DMAD dihydrochloride inhibits IRE1α oligomerization and endoribonuclease (RNase) activity. 3,6-DMAD dihydrochloride can be used for research of cancer .
    3,6-DMAD dihydrochloride
  • HY-144226
    NLRP3/AIM2-IN-3
    4 Publications Verification

    		 NOD-like Receptor (NLR) AIM2 Pyroptosis Inflammation/Immunology
    NLRP3/AIM2-IN-3 (compound 59) is a potent inhibitor with differential species specific effects against NLRP3 and AIM2 inflammasome-dependent pyroptosis. NLRP3/AIM2-IN-3 shows inhibitory efficacy against pyroptosis in THP-1 macrophages stimulated with LPS/nigericin, with an IC50 of 0.077 ± 0.008 μM. NLRP3/AIM2-IN-3 disturbs the interaction of NLRP3 or AIM2 with the adaptor protein ASC and inhibited ASC oligomerization .
    NLRP3/AIM2-IN-3
  • HY-108937
    NSC 15364
    5+ Cited Publications

    		 VDAC Apoptosis Cardiovascular Disease Neurological Disease
    NSC 15364 is an inhibitor of VDAC1 oligomerization and apoptosis .
    NSC 15364
  • HY-145580A
    (S)-Minzasolmin

    (S)-UCB0599; (S)-NPT200-11

    		 α-synuclein Neurological Disease
    (S)-Minzasolmin is an isomer of minzasolmin (HY-145580), an inhibitor of α-synuclein oligomerization .
    (S)-Minzasolmin
  • HY-118948
    MSN-50

    		Bcl-2 Family Neurological Disease
    MSN-50 is a Bax and Bak oligomerization inhibitor. MSN-50 efficiently inhibits liposome permeabilization, prevents genotoxic cell death and promotes neuroprotection .
    MSN-50
  • HY-161743
    PBA-1105

    		AUTOTACs Autophagy Cancer
    PBA-1105 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105 increases the autophagic flux of Ub-conjugated aggregates .
    PBA-1105
  • HY-161744
    PBA-1106

    		AUTOTACs Autophagy Cancer
    PBA-1106 is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1106 increases the autophagic flux of Ub-conjugated aggregates .
    PBA-1106
  • HY-161742
    Fumagilin-105

    		AUTOTACs Estrogen Receptor/ERR Autophagy p62 Cancer
    Fumagilin-105 is an autophagy targeting chimera (AUTOTAC) that induces p62 self-oligomerization with DC50 values of 0.7 μM for MetAP2 in HEK293 cells .
    Fumagilin-105
  • HY-18633
    MDK83190

    		Apoptosis Cancer
    MDK83190 is a potent apoptosis activator, induces Apaf-1 oligomerization, increases procaspase-9 processing and subsequent caspase-3 activation in a cyto c-dependent Manner .
    MDK83190
  • HY-100691
    NOD-IN-1
    5+ Cited Publications

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    NOD-IN-1 is a potent mixed inhibitor of nucleotide-binding oligomerization domain (NOD)-like receptors, NOD1 and NOD2, with IC50 of 5.74 μM and 6.45 μM, respectively.
    NOD-IN-1
  • HY-119519
    OB-2

    		Others Neurological Disease
    OB-2 is a STOML3 oligomerization blocker. OB-2 reverses pathological mechanical hypersensitivity. OB-2 can be used for research of painful diabetic neuropathy in mice .
    OB-2
  • HY-18937
    WEHI-345
    3 Publications Verification

    		 RIP kinase Cancer
    WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
    WEHI-345
  • HY-103349
    PETCM
    1 Publications Verification

    		 Caspase Apoptosis Cancer
    PETCM is an activator of caspase-3 and acts as an cytochrome c (cyto c)-dependent manner. PETCM promotes Apaf-1 oligomerization and induces cell apoptosis in HeLa cells .
    PETCM
  • HY-122671
    OB-1

    		Others Neurological Disease
    OB-1 is a stomatin-like protein-3 (STOML3) oligomerization blocker. OB-1 is an effective inhibitor of the self-association of Stomatin, STOML1 and STOML2, but not podocin .
    OB-1
  • HY-149233
    hAChE-IN-1

    		Cholinesterase (ChE) Tau Protein Neurological Disease
    hAChE-IN-1 (Compound 24) is a potent hAChE inhibitor with an IC50 of 1.09 μM. hAChE-IN-1 inhibits tau-oligomerization with an EC50 of 2.71 μM in cellular tau FRET assay .
    hAChE-IN-1
  • HY-158405
    PAV-104

    		SARS-CoV Infection
    PAV-104 inhibits SARS-CoV-2 replication, with the MOI of 0.01. PAV-104 can interact with SARS-CoV-2 nucleocapsid (N) and interfered with its oligomerization, blocking particle assembly .
    PAV-104
  • HY-100112
    WEHI-345 analog

    		RIP kinase Others
    WEHI-345 analog is the analog of WEHI-345. WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC50 of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation .
    WEHI-345 analog
  • HY-163358
    SLC3037
    1 Publications Verification

    		 NOD-like Receptor (NLR) NEKs Cardiovascular Disease Neurological Disease Inflammation/Immunology
    SLC3037 is a NLRP3 inhibitor which blocks NLRP3 from binding to NEK7 or oligomerization, inhibiting inflammasome caused by MSU and other inflammasome activators. SLC3037 can be used for research of gout, cardiovascular diseases, metabolic syndrome or neurodegenerative diseases .
    SLC3037
  • HY-150147
    CAM833

    		RAD51 Apoptosis Cancer
    CAM833 is a potent orthosteric inhibitor of the interaction between BRCA2 and RAD51 with a Kd of 366 nM against the ChimRAD51 protein. CAM833 also inhibits RAD51 oligomerization. CAM833 increases the progression of G2/M-arrested cells into apoptosis .
    CAM833
  • HY-123572
    Bis-T-23

    AG1717

    		 Dynamin HIV Integrase Infection Metabolic Disease Inflammation/Immunology
    Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD) .
    Bis-T-23
  • HY-W688687
    XIE62-1004-A

    		Autophagy p62 Atg8/LC3 Others
    XIE62-1004-A is an inducer of p62-LC3 interaction. XIE62-1004-A can bind to the ZZ-domain of p62, inducing p62 oligomerization and activating p62-dependent autophagy .
    XIE62-1004-A
  • HY-17406
    Tolcapone
    2 Publications Verification

    Ro 40-7592

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone
  • HY-161745
    PBA-1105b

    		AUTOTACs p62 Autophagy Cancer
    PBA-1105b is an autophagy-targeting chimera (AUTOTAC) that induces p62 self-oligomerization. PBA-1105b increases the autophagic flux of Ub-conjugated aggregates. PBA-1105b is a drastically longer PEG-based linker than PBA-1105 .
    PBA-1105b
  • HY-136555
    GSK717
    5+ Cited Publications

    		 NOD-like Receptor (NLR) Inflammation/Immunology
    GSK717 is a potent, selective NOD2 (nucleotide-binding oligomerization domain 2) inhibitor. GSK717 inhibits muramyl dipeptide (MDP)-induced NOD2-mediated signaling, with an IC50 of 400 nM for MDP-stimulated IL-8 secretion in HEK293/hNOD2 cells .
    GSK717
  • HY-18509
    IRE1α kinase-IN-2

    		IRE1 Cancer
    IRE1α kinase-IN-2 is a potent IRE1α kinase inhibitor, with an EC50 of 0.82 μM. IRE1α kinase-IN-2 inhibits IRE1α kinase autophosphorylation (IC50=3.12 μM). IRE1α kinase-IN-2 inhibits XBP1 mRNA splicing in the WT cell lines .
    IRE1α kinase-IN-2
  • HY-161740
    PHTPP-1304

    		AUTOTACs Estrogen Receptor/ERR Autophagy Cancer
    PHTPP-1304 is a PHTPP-based autophagy targeting chimera (AUTOTAC) that induces p62 self-oligomerization and degradation of estrogen receptor ERβ (DC50:~2 nM, HEK293T). PHTPP-1304 also induces the formation of p62 +ERβ + puncta that are affected by autophagic flux in a dose-dependent manner .
    PHTPP-1304
  • HY-168159
    TLR7 agonist 27

    		Toll-like Receptor (TLR) NOD-like Receptor (NLR) Inflammation/Immunology
    TLR7 agonist 27 (compound 24) is a potent TLR7 agonist with an EC50 of 238.1 nM. TLR7 agonist 27 shows weak agonistic activity against NOD2 (nucleotide-binding oligomerization domain 2) (EC50 of 6.2 μM). TLR7 agonist 27 is a potent immunostimulant, and can be used as a vaccine adjuvant and/or immunotherapeutic .
    TLR7 agonist 27
  • HY-17406S1
    Tolcapone-d4

    Ro 40-7592-d4

    		 Isotope-Labeled Compounds COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone-d4 is the deuterium labeled Tolcapone. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver[1]. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis[2]. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma[3].
    Tolcapone-d4
  • HY-100432
    LOC14
    2 Publications Verification

    		 PDI Neurological Disease Inflammation/Immunology
    LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding . LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells .
    LOC14
  • HY-17406R
    Tolcapone (Standard)

    Ro 40-7592 (Standard)

    		 COMT Amyloid-β Apoptosis Neurological Disease Cancer
    Tolcapone (Standard) is the analytical standard of Tolcapone. This product is intended for research and analytical applications. Tolcapone (Ro 40-7592) is a selective, orally active and powerful mixed (peripheral and central) COMT inhibitor with an IC50 of 773 nM in the liver . Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis . Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in neuroblastoma .
    Tolcapone (Standard)
  • HY-161242A
    CBI1 formic

    		Bcl-2 Family Cancer
    CBI1 formic is a covalent BAX inhibitor. CBI1 formic selectively derivatizes BAX at C126 and inhibits BAX activation by triggering ligands or point mutagenesis. CBI1 formic blocks t-2-hex lipidation and oligomerization of BAX. CBI1 formic inhibits BAX activation induced by BH3 ligands, F116A mutagenesis or t-2-hex .
    CBI1 formic
  • HY-149393
    RIPK3-IN-3

    		Mixed Lineage Kinase RIP kinase Cancer
    RIPK3-IN-3 (compound 20) is a selective inhibitor of RIP kinase RIPK3 (IC50=10 nM). RIPK3 mediates the phosphorylation of Mixed Lineage Kinase (MLKL) and causes necroptosis, while RIPK3-IN-3 inhibits p-MLKL oligomerization and thereby inhibits necroptosis. RIPK3-IN-3 also downregulates CXCL5 secretion and inhibits AsPC-1 cell migration and invasion .
    RIPK3-IN-3
  • HY-157214
    NVS-STG2

    		STING Cancer
    NVS-STG2 is a molecular glue that targets STING and activates STING-mediated immune signaling. NVS-STG2 induces higher-order oligomerization of human STING by binding to pockets between adjacent STING dimer transmembrane domains, effectively acting as a molecular glue. NVS-STGI enhances the activity of cGAMP by inducing the formation of more abundant and larger oligomers. NVS-STG2 produces antitumor activity in animal models .
    NVS-STG2
  • HY-156119
    MLKL-IN-6

    		Mixed Lineage Kinase Necroptosis Metabolic Disease Cancer
    MLKL-IN-6 (compound P28) is a mixed lineage kinase inhibitor targeting Mixed Lineage Kinase domain-like (MLKL). MLKL-IN-6 inhibits cell necrosis. MLKL-IN-6 inhibits MLKL phosphorylation and oligomerization during cell necrosis, inhibits immune cell death, and reduces the expression of adhesion factors. MLKL-IN-6 has low cytotoxicity, and it inhibits hepatic stellate cell activation, reduces liver fibrosis marker levels, and has anti-fibrotic effects .
    MLKL-IN-6
  • HY-161072
    CSC-6

    		NOD-like Receptor (NLR) Inflammation/Immunology
    CSC-6 is a NLRP3 inhibitor. CSC-6 can significantly inhibit IL-1β secreted by PMATHP-1 cells with an IC50 value of 2.3 μM. CSC-6 specifically binds NLRP3 and inhibits NLRP3 activation by blocking ASC oligomerization during NLRP3 assembly. CSC-6 effectively reduces the symptoms of NLRP3 overactivation-mediated sepsis and gout in mouse models .
    CSC-6
  • HY-146034
    NOD1/2 antagonist-1

    		NOD-like Receptor (NLR) Inflammation/Immunology Cancer
    NOD1/2 antagonist-1 (compound 36b) is a potent NOD1/2 (nucleotide-binding oligomerization domain-like receptor 1/2) dual antagonist, with IC50 values of 1.13 (NOD1) and 0.77 μM (NOD2), respectively. NOD1/2 antagonist-1 has a acceptable T1/2 (67.6 min). NOD1/2 antagonist-1 (compound 36b) can improve the antitumor efficacy of Paclitaxel (PTX) .
    NOD1/2 antagonist-1

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: